Literature DB >> 9028700

Low prevalence of islet autoantibodies in patients with gestational diabetes mellitus.

N Dozio1, A Beretta, C Belloni, M Castiglioni, S Rosa, E Bosi, E Bonifacio.   

Abstract

OBJECTIVE: To determine the proportion of patients with gestational diabetes mellitus (GDM) who have serological characteristics typical of IDDM. RESEARCH DESIGN AND METHODS: Islet cell antibodies (ICAs), insulin autoantibodies (IAAs), GAD65, and IA-2 antibodies were measured in 145 pregnant women with GDM, 33 with impaired glucose tolerance (IGT), and in 73 with normal glucose tolerance (NGT). ICAs were measured by indirect immunofluorescence; GAD65 and IA-2 antibodies, by a radio-ligand immunoassay incorporating 35S-labeled recombinant antigen; and IAAs, by a liquid-phase radiobinding assay.
RESULTS: The prevalences of islet autoantibodies were low and not significantly different between groups. ICAs were detected at levels ranging from 5 to 45 Juvenile Diabetes Foundation U in 14 (10%) women with GDM, 2 (6%) women with (GT, and in 4 (5%) women with NGT. IAAs were detected at levels between 3 and 4 SD above the mean in 4 (3%) women with GDM, 0 women with IGT, and in 1 (1%) woman with NGT. None had both ICAs and IAAs. Neither GAD65 nor IA-2 antibodies, which have been detected in the majority of pre-IDDM and IDDM patients, were found in NGT, IGT, or GDM patients.
CONCLUSIONS: Low-titer ICAs and IAAs are not infrequent in pregnant women, but multiple islet autoantibodies and antibodies to GAD65 or IA-2 were not found in GDM. These findings suggest that the serological characteristics of IDDM are rare in GDM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028700     DOI: 10.2337/diacare.20.1.81

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

Review 1.  Current controversies in the mechanisms and treatment of gestational diabetes.

Authors:  Gyula Tamás; Zsuzsa Kerényi
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

2.  Immune responses to glutamic acid decarboxylase and insulin in patients with gestational diabetes.

Authors:  M Füchtenbusch; E Bonifacio; V Lampasona; A Knopff; A-G Ziegler
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

3.  Genotypic and phenotypic differences between Arabian and Scandinavian women with gestational diabetes mellitus.

Authors:  N Shaat; M Ekelund; A Lernmark; S Ivarsson; A Nilsson; R Perfekt; K Berntorp; L Groop
Journal:  Diabetologia       Date:  2004-04-17       Impact factor: 10.122

4.  Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up.

Authors:  E Cossu; M Incani; M G Pani; G Gattu; C Serafini; A Strazzera; L Bertoccini; F A Cimini; I Barchetta; M G Cavallo; M G Baroni
Journal:  J Endocrinol Invest       Date:  2018-01-16       Impact factor: 4.256

5.  Type 1 diabetes-related autoimmune antibodies in women with gestational diabetes mellitus and the long-term risk for glucose intolerance.

Authors:  Kaat Beunen; Lies Vercauter; Paul Van Crombrugge; Carolien Moyson; Johan Verhaeghe; Sofie Vandeginste; Hilde Verlaenen; Chris Vercammen; Toon Maes; Els Dufraimont; Nele Roggen; Christophe De Block; Yves Jacquemyn; Farah Mekahli; Katrien De Clippel; Annick Van Den Bruel; Anne Loccufier; Annouschka Laenen; Roland Devlieger; Chantal Mathieu; Katrien Benhalima
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-24       Impact factor: 6.055

6.  Autoimmunity in gestational diabetes mellitus in Sardinia: a preliminary case-control report.

Authors:  Cinzia Murgia; Marisa Orrù; Elaine Portoghese; Nicoletta Garau; Pierina Zedda; Rachele Berria; Costantino Motzo; Simonetta Sulis; Michela Murenu; Anna Maria Paoletti; Gian Benedetto Melis
Journal:  Reprod Biol Endocrinol       Date:  2008-06-29       Impact factor: 5.211

7.  Testing for type 1 diabetes autoantibodies in gestational diabetes mellitus (GDM): is it clinically useful?

Authors:  Michela Incani; Marco Giorgio Baroni; Efisio Cossu
Journal:  BMC Endocr Disord       Date:  2019-05-03       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.